RA Capital Management’s Larimar Therapeutics LRMR Stock Holding History

RA Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-6,045,351	Closed	-$19.5M	–	80
2025 Q3	$19.5M	Hold	6,045,351	–	–	0.24%	43
2025 Q2	$17.5M	Hold	6,045,351	–	–	0.29%	36
2025 Q1	$13M	Hold	6,045,351	–	–	0.22%	59
2024 Q4	$23.4M	Hold	6,045,351	–	–	0.31%	54
2024 Q3	$39.6M	Hold	6,045,351	–	–	0.46%	43
2024 Q2	$43.8M	Hold	6,045,351	–	–	0.58%	43
2024 Q1	$45.9M	Buy	+6,045,351	New	+$47.1M	0.58%	43
2022 Q3	–	Sell	-1,031,482	Closed	-$2.02M	–	90
2022 Q2	$2.02M	Sell	1,031,482 -250,378	-20%	-$740K	0.05%	81
2022 Q1	$5.19M	Sell	1,281,860 -52,750	-4%	-$345K	0.11%	88
2021 Q4	$14.4M	Sell	1,334,610 -180,541	-12%	-$2.01M	0.25%	68
2021 Q3	$17.5M	Hold	1,515,151	–	–	0.24%	65
2021 Q2	$14.9M	Hold	1,515,151	–	–	0.24%	61
2021 Q1	$22.1M	Hold	1,515,151	–	–	0.33%	54
2020 Q4	$32.4M	Hold	1,515,151	–	–	0.45%	50
2020 Q3	$23M	Hold	1,515,151	–	–	0.42%	46
2020 Q2	$19.5M	Buy	+1,515,151	New	+$17.6M	0.38%	41
2015 Q2	–	Sell	-61,080	Closed	-$29M	–	63
2015 Q1	$29M	Hold	61,080	–	–	2.88%	12
2014 Q4	$22.6M	Hold	61,080	–	–	2.43%	13
2014 Q3	$14.4M	Buy	+61,080	New	+$13.8M	1.7%	18

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

RA Capital Management's LRMR Position: Q4 2025 in Review

RA Capital Management sold out of Larimar Therapeutics (LRMR) in Q4 2025, closing a stake of 6,045,351 shares — an estimated $19.5M sold.

RA Capital Management first reported a position in LRMR in Q3 2014 and held it in 19 quarters. The position peaked at $45.9M in Q1 2024. 136 funds tracked by Wall St. Rank hold LRMR as of Q4 2025.

RA Capital Management reported no remaining Larimar Therapeutics position as of Q4 2025 after selling out during the quarter.
RA Capital Management sold 6,045,351 Larimar Therapeutics shares in Q4 2025, an estimated $19.5M.
RA Capital Management first reported a position in Larimar Therapeutics in Q3 2014 and held it in 19 quarters.
RA Capital Management's Larimar Therapeutics position peaked at $45.9M in Q1 2024.
136 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2025.

Based on RA Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.